- Precision BioSciences Inc Extraordinary Shareholders Meeting TranscriptJan 18, 2024
- Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Precision BioSciences Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- Precision BioSciences Inc Annual Shareholders Meeting TranscriptMay 04, 2023
- Precision BioSciences Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) TranscriptApr 03, 2023
- Precision BioSciences Inc at HC Wainwright Cell Therapy Virtual Conference TranscriptFeb 28, 2023
- Precision BioSciences Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 13, 2022
- Precision BioSciences Inc Announces In Vivo Gene Editing Collaboration with Novatris TranscriptJun 22, 2022
- Precision BioSciences Inc Allogeneic CAR T Update- Conference Call TranscriptJun 08, 2022
- Precision BioSciences Inc Annual Shareholders Meeting TranscriptMay 10, 2022
- Precision BioSciences Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 27, 2021
- Precision BioSciences Inc PBCAR0191 Clinical Data Call TranscriptJun 04, 2021
- Precision BioSciences Inc Annual Shareholders Meeting TranscriptMay 10, 2021
- Precision BioSciences Inc Reacquires Global Rights to its Allogeneic CAR T Programs- Conference Call TranscriptApr 15, 2021
- Precision BioSciences Inc at Truist Securities Life Sciences Summit (April Series) TranscriptApr 13, 2021
- Precision BioSciences Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Cell Gene Meeting on the Mesa - Precision BioSciences TranscriptJan 08, 2021
- Precision BioSciences Inc Interim Data Results for PBCAR0191- Conference Call TranscriptDec 04, 2020
- Precision BioSciences Inc and Eli Lilly and Co In Vivo Gene Editing Collaboration - Conference Call TranscriptNov 20, 2020
Cell Gene Meeting on the Mesa - Precision BioSciences Transcript
Hello. My name is Cindy Atwell, and I'm VP of Business Development at Precision BioSciences. We are a clinical stage biotechnology company leveraging a next-generation genome editing platform for the development of therapeutics. We are a public company and I will be making forward-looking statements today. Please refer to the disclosures and risk factors in our SEC filings.
Precision BioSciences is dedicated to improving life through the application of our proprietary ARCUS genome editing platform. The focus of Precision BioSciences is to create therapeutics that address unmet medical needs.
Applying ARCUS, we are seeking to overcome cancer through the development of allogeneic CAR T therapies and the cure of rare diseases through in vivo gene correction. Our wholly owned subsidiary, Elo Life Systems also placed the ARCUS platform to improve human health through food. It has been an exciting year at Precision during which we have built a world-class team of 220 employees. We've established a GMP manufacturing facility and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)